Missouri Department of Health launches digital access for immunizations
According to the Missouri Department of Health and Senior Services (DHSS), people in Missouri can review, download and share their immunization records through a mobile app called Docket and their web platform.
The service expands digital access for school, travel, health and personal use.
Missourians can use Docket to access personal and family immunization records on file with the Missouri Immunization Registry. Depending on individual providers' practices, it is possible for someone not to see all of their vaccinations in this system.
How to get a spot at Patrick Mahomes, Travis Kelce's new steakhouse 1587 Prime
Docket also allows residents to do the following:
View, download and share their personal immunization history.
Access records for children or individuals for whom they are a parent, legal guardian or authorized representative.
Share official immunization documentation with schools, camps, health providers and travel officials.
According to DHSS, immunization rates for Missouri kindergartners has declined. These were following rates for the 2024-25 school year:
DTaP: 90.0%
Hep B: 92.7%
IPV/Polio: 90.7%
MMR: 90.0%
Varicella: 89.4%
For more information about Docket and immunizations, you can click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health
The Investment is part of BrainsWay's ongoing strategy to acquire minority positions in leading U.S. mental health providers to help them raise awareness for and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Aug. 20, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ('BrainsWay' or the 'Company'), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has entered into a strategic equity financing agreement with Axis Management Company, Inc. ('Axis Integrated Mental Health' or 'Axis'), a management services organization servicing several mental health clinics in Colorado. Under the terms of the agreement, BrainsWay will invest $2.3 million initially, and an additional potential $1 million milestone-based investment, for a minority position in Axis in the form of a preferred, annually compounding security. The agreement also provides for a redemption mechanism relating to the shares. 'Our minority-stake investment in Axis follows our previous investment in Stella, and is part of BrainsWay's broader initiative to accelerate access to and awareness of innovative mental health treatments, including Deep TMS Therapy, while continuing to maintain our core focus on advancing our scientific and technological capabilities to ensure best-in-class support for all our customers. Within this strategy, our investments provide capital injections into high performing healthcare providers, which then allows these businesses to invest in growth drivers and launch new locations,' said Hadar Levy, Chief Executive Officer of BrainsWay. 'We see tremendous opportunities for these healthcare providers to offer expanded services and grow their businesses once they secure the necessary capital.' 'Axis offers a robust clinical services platform and is committed to achieving rapid growth and excellent patient outcomes. We are thrilled to support and collaborate with them as their business continues to scale from a well-respected regional platform to one with a larger footprint, enhancing their delivery of life-changing care to additional patients,' concluded Mr. Levy. 'Our partnership with BrainsWay was born out of a mutual desire to deliver the best cutting-edge mental health treatments to the communities we serve,' stated Chris Perez, Chief Executive Officer of Axis. 'Given the peerless reputation of BrainsWay and its proprietary Deep TMS technology, we realize the value this strategic partnership will provide as we further advance in our mission of putting patients first through our best-in-class support.' About BrainsWay BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit About Axis Axis Integrated Mental Health services its leading mental health practices, which are dedicated to transforming lives through a truly comprehensive, integrative model of care. With a team of board-certified specialists combining modern psychiatry and psychotherapy with advanced treatments including Deep TMS™ and Spravato®, Axis utilizes an evidence-based, holistic therapeutic approach to treat patients, all through a single, coordinated care experience under one roof. For more information, please visit Forward-Looking Statement This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential' or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the failure of our investments in management services organizations and/or other clinic-related entities to produce profitable returns; inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company's anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company's intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading 'Risk Factors' in the Company's filings with the U.S. Securities and Exchange Commission. Contacts: BrainsWay:Ido MaromChief Financial Investors:Brian RitchieLifeSci Advisors LLCbritchie@ in to access your portfolio
Medscape
6 minutes ago
- Medscape
UK Clinicians Want Clearer AI Guidance and Oversight
Artificial intelligence (AI) is playing a growing role in healthcare worldwide, but UK clinicians remain cautious, citing practical and ethical concerns, research has revealed. Alongside rising global adoption, regulators are moving to address safety and trust. The Medicines and Healthcare products Regulatory Agency (MHRA) has joined as a founding member of the new Health AI Global Regulatory Network, positioning the UK at the forefront of international oversight. Global Uptake Rising, UK Lags Behind Elsevier's Clinician of the Future 2025 report, published last month, surveyed 2206 clinicians (1781 doctors and 425 nurses) in 109 countries. The responses included answers from 78 UK doctors or physician associates and 31 nurses. Nearly half of respondents globally (48%) reported using AI at work, almost double the 2024 figure of 26%. In the UK, uptake was lower. Only 34% of UK clinicians reported using AI at work, with just 21% of doctors doing so. Common uses included identifying drug interactions (20%), writing clinical notes (18%), second opinions (18%), patient letters (16%), analysing medical images (15%), medication summaries (12%), and multidisciplinary reviews of complex cases (8%). Despite high patient volumes — 60% of UK clinicians said they lacked time to deliver good care, compared with 74% globally — many felt digital diagnostic tools remained inadequate. Scepticism and Distrust UK clinicians were more sceptical than average about AI's potential benefits and were less likely to use it for clinical decision-making, with 53% indicating they would not, and 45% saying they would not rely on AI tools for second opinions. Thirty-three percent described AI as unreliable, compared with 23% who considered it trustworthy. Dr Rahul Goyal, clinical executive at Elsevier and a practising GP, told Medscape News UK that caution reflects the NHS's structure. He cited strict regulatory oversight, national guidelines, evidence-based practice, and accountability as factors. 'While these priorities help safeguard patient care, they can also make clinicians more cautious about adopting new technologies like AI,' he said. He also pointed to 'tech debt' within NHS systems, with many still paper-based and lacking routine clinical decision support. 'As a result, clinicians are understandably more sceptical about using new technologies,' Goyal said. Confidentiality and Trust Most Key When asked what would increase their confidence in AI, 81% of UK clinicians highlighted data confidentiality. The same proportion wanted AI tools trained for factual accuracy, morality, and safety — well above the 63% global average. Trust in international governance was low. Just 27% of UK respondents said they trusted their organisation's AI oversight. Globally, 74% said clearer guidance on AI use would boost trust. The findings align with concerns expressed in Medscape's September 2024 UK Doctors and AI Report. It found that while more than half of clinicians were enthusiastic about the future of AI in healthcare, 1 in 3 of the 745 respondents lacked confidence that it could ensure confidentiality. The vast majority (83%) agreed there was a need for oversight of AI in healthcare settings. Push for Regulation A General Medical Council report earlier this year echoed these concerns, with doctors warning that NHS IT systems must improve before wider adoption. Respondents highlighted concerns about confidentiality risks, over-reliance, de-skilling, errors, and lack of independent evaluation. Many called for regulators to provide more guidance. The lower adoption rate of AI in the UK 'underscores the prevailing caution, and reinforces the need for greater integration, clear guidance, and reassurance as AI becomes more prominent in UK healthcare,' Goyal said. He expressed support for the MHRA's leading role in the new Health AI Global Regulatory Network, describing it as 'a proactive step toward addressing clinicians' concerns.' AI and digital tools are reshaping healthcare, he said, but 'their success depends on building systems that empower clinicians to use them confidently and responsibly.' Looking Ahead While concerns persist, many clinicians see potential benefits. Nearly half (46%) of UK respondents said AI could improve consultation quality, and 62% expected it to improve patient outcomes within 3 years. Goyal said that success depends on integration into NHS systems, clinician training, and patient acceptance. 'If AI is used as a tool to improve access, enhance communication, and empower patients with information, then it is a win,' he said. 'However, if it is poorly implemented or perceived as impersonal, it could widen the gap between GPs and patients.'
Medscape
6 minutes ago
- Medscape
The Vaccination Talk: Tips and Scripts
The new school year is here, and if history repeats itself, vaccination rates will continue declining and exemptions rising. It can translate to a difficult office visit for primary care physicians trying to keep their patients as healthy as possible. Among US kindergartners, vaccination coverage decreased for all reported vaccines during the 2024-2025 school year compared with the year before, according to CDC data. An estimated 286,000 kindergartners attended school last year without completing the measles-mumps-rubella (MMR) series — and 1356 confirmed measles cases have been reported this year as of August 6. We asked four primary care doctors from four different states to share their scripts and tips for the often-difficult vaccination conversation. Carlos O'Bryan-Becerra, MD: Repeat, Repeat, Repeat. Plant the Seed An obstetric patient was positive for hepatitis B virus (HBV) and a vaccine skeptic. Both the mother- and father-to-be were against giving the baby the hepatitis B vaccine. 'We know the risk of transmission is high,' O'Bryan-Becerra, a family physician in Ventura, California, and a core faculty member of the Ventura County Medical Center residency program, told the couple. Carlos O'Bryan-Becerra, MD He explained a vaccination is routinely recommended for all infants at birth, and that hepatitis B immune globulin is also recommended for infants whose mother is infected with HBV to reduce the risk of the infant becoming infected during the pregnancy or at delivery. He pointed out that an infant who contracts hepatitis B has a higher risk of later getting cirrhosis and cancer. Still, the couple refused the vaccine when the newborn arrived. 'They said many doctors didn't believe [it was needed] and that big pharma was behind why we vaccinate babies,' said O'Bryan-Becerra. He kept trying, stressing the facts and that he vaccinated his own children. In the end, he was able to convince them. 'We got guidance from the [hospital] ethics committee,' he said. 'In some states, there is a lot more leniency [for exemptions]. In California, there are medical exemptions only.' There was no validated medical information that would point to a need for a medical exemption. 'So, the vaccination was clearly standard of care,' said O'Bryan-Becerra. He said that if the parents were not willing to follow the standard of care, he would have to reach out to child protective services. 'When I brought this up, the parents decided they were willing to go ahead and vaccinate the child.' 'I've been practicing 17 years and never had a scenario like this,' he said. He plans to continue talking to reluctant parents, visit after visit. He tells them: 'I know you're sick of me talking about this. But you know I bring this up because I care.' He may not convince them at that visit, but he hopes he is at least planting the seed. Emily Briggs, MD, FAAFP: Meet the Patients Where They Are Meeting the patient who is hesitant about vaccines where they are — and understanding where they got their vaccine information — is uppermost in the mind of Briggs, honorary FACOG, a private practice family physician in New Braunfels, Texas. Emily Briggs, MD, FAAFP Recently, a parent shared an unbelievable reason for declining a vaccine for her child: 'I saw if I give this vaccine to my child, it's going to make spoons stay attached to her,' she said. She elaborated, 'My child will become magnetized.' Briggs got to the source of the misinformation — a social media post. 'I went and looked for it,' Briggs said. It turned out the original post wasn't about a childhood vaccine but the COVID vaccine, and the claim had circulated widely in 2021, along with other false claims about the vaccine. At the time, the CDC debunked it quickly. Briggs told the mother what was in the vaccine her child needed and talked about decades of research on safety and effectiveness. She talked about the danger of misinformation and that some studies have been retracted or that claims on social media have been debunked. She often points to the retraction, in 2010, of the Andrew Wakefield research falsely claiming a link between the MMR vaccine and autism, first published in 1998 and later disproven. While it happened years ago, Briggs said she brings it up because parents who are unaware of the retraction still do. The parent with the magnetizing concerns agreed to let her child receive some vaccines that day. 'A month later, they came for the other half of the 2-month-old vaccines,' said Briggs, who agreed to that schedule. 'When parents can see my humanity meeting their humanity, and that we both have the best intent, we can often find common ground,' Briggs said. Brent Smith, MD, MSc, FAAFP: Watch the Body Language Pushback about mandates for COVID vaccines 'has trickled over into all vaccines in this area,' said Smith, a family physician in Greenville, Mississippi, and a board member of the American Academy of Family Physicians. Brent Smith, MD, MSc, FAAFP When parents arrive at his office with a child due for an immunization, he has learned to watch the body language. When the conversation focuses on vaccines, those who are hesitant often will tense up, he said. 'Their body language will change, or they will become a little more guarded.' Recently, when the parent of a 2-year-old brought her in for a yearly checkup, Smith reminded her that the child was behind on routine vaccines. The mother's body language changed, so he asked immediately what she'd heard that was making her uncomfortable. Most often, it's misinformation from friends or the internet. 'You have to address it step by step,' he said, telling them what the truth is. Addressing the misinformation directly and providing them with facts can give them a different perspective. The mother was strongly against the COVID and flu vaccines, in particular. Smith explained the differences between COVID and flu and their vaccines but decided for this visit to focus on the other recommended vaccines, especially as flu season was done. When Smith focused on the other vaccines that the mother didn't oppose as strongly, the mother agreed for her child to catch up with the diphtheria-tetanus-pertussis, MMR, and hepatitis A vaccines. Smith said he's learned to keep perspective. 'Sometimes you have to compromise and say, 'What's the most important thing I can address or get done today?'' James B. Bigham, MD, MPH, FAAFP: 'Assume It's a Yes' In years past, pre-pandemic, physicians and patients often just assumed they'd get recommended vaccines, said Bigham, a clinical professor of family medicine and community health at the University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 'That's changed. People are opting out for various reasons.' James B. Bigham, MD, MPH, FAAFP, So, it's crucial, he said, to demonstrate confidence about vaccines — and to assume the answer will be yes. He calls it 'having a presumptive approach.' When a patient comes in and is due for a vaccine, he tells them: 'Today is a good day to give the vaccine.' If there's pushback, he said, it's important to listen to the questions. He repeats his recommendation and describes the illness the vaccine is designed to prevent. For instance: 'I strongly recommend you receive the influenza vaccine because it could make you really sick…and you might miss a couple weeks of work, or your child might miss a week or 2 of school.' Consider that some parents have no firsthand experience with some vaccine-preventable illnesses, he said, and that could explain their hesitancy. They wonder what chickenpox is, for instance, since they got the vaccine as children and have never seen a case. He takes time to answer those questions. 'It's so important now not to be dismissive,' he said.
